Inimmune is a leading vaccine adjuvant and immunotherapy company utilizing the human immune system to prevent and treat disease.

About the company

Inimmune is a clinical-stage immunotherapy biotech company with a deep pipeline of vaccine adjuvants and immunotherapeutics advancing potential breakthroughs in human health. With a full suite of state-of-the-art preclinical labs and an extensive network of collaborations with top-tier researchers across the country, Inimmune has a growing pipeline of disruptive technologies and the capability to advance these from early discovery to clinical use. The leading R&D team’s performance has been validated with the awarding of several large National Institute of Health contracts and grants which directly contribute to the advancement of novel adjuvants and immunotherapies. Inimmune’s disease-modifying treatments are expected to make major impacts in the allergy, cancer and vaccine fields in the years to come for the betterment of humankind. Visit inimmune.com.

Go Back to portfolio